Trial Profile
Administration of Autologous Neomycin Resistant Gene Marked EBV Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving Autologous Bone Marrow Transplant for Relapsed EBV-Positive Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2021
Price :
$35
*
At a glance
- Drugs Baltaleucel-T (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms ANGELA
- 08 Aug 2014 New trial record